Ganga Pharmaceuticals Limited is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 2 | 3 | 3 | 3 | 3 |
| EBITDA (ex other income) | — | — | — | — | — |
| margin % | — | — | — | — | — |
| Owners' profit | — | — | — | — | — |
| EPS, as reported (₹) | 0.09 | 0.10 | 0.11 | 0.16 | 0.17 |
| ROE % · ROCE % | — · 3.9 | — · 4.1 | — · 3.3 | — · 3.7 | — · 3.1 |
| Debt / equity (x) | — | — | — | — | — |
| Cash from operations | (0) | (0) | (1) | (1) | (1) |
| Capex | — | — | — | 0 | (0) |
| ₹ crore | Q2 FY23 | Q4 FY23 | Q2 FY24 | Q4 FY24 | Q2 FY25 | Q4 FY25 | Q2 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | — | — | — | — | — | — | — | — |
| EPS (₹) | 0.08 | 0.02 | 0.04 | 0.07 | 0.05 | 0.11 | 0.04 | 0.13 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 2 Sept 2026 · Newspaper Publication for 37th AGM of Ganga Pharmaceuticals Limited | compliance | minimal | — | — |
| 1 Sept 2026 · AGM Notice Sent to Shareholders Without Registered Email IDs | compliance | minimal | — | — |
| 1 Sept 2026 · Notice of 37th AGM on September 26, 2026 with director re-appointment | board shareholder meetings | low | — | — |
| 1 Sept 2026 · Ganga Pharmaceuticals reports higher FY26 profit, sets September AGM | board shareholder meetings | low | — | — |
| 1 Sept 2026 · 37th AGM on Sep 26, 2026; MD re-appointment and FY26 results on agenda | board shareholder meetings | low | — | — |
| 10 Jul 2026 · Quarterly demat certificate filed with BSE for Q1 FY27 | compliance | minimal | — | — |
| 9 Jul 2026 · Newspaper notice on special window for physical share re-lodgement | compliance | minimal | — | — |
| 28 May 2026 · Non-Applicability of Annual Secretarial Compliance Report for the Financial Year ended March 31, 2026 | compliance | minimal | — | — |
| 21 May 2026 · Appointment of Secretarial Auditor | management changes | medium | — | — |
| 21 May 2026 · Appointment of Internal Auditor | management changes | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 37.9 | 28.9 | 107 of 169 | 37% |
| ROCE | 1.5 | 10.8 | 143 of 183 | 22% |
| Revenue growth | 3.2 | 16.3 | 118 of 161 | 27% |
| Market cap | 7 | 839 | 177 of 182 | 3% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
